Search filters

Filters
Clear All

Phase

  • 183
  • 156
  • 2
  • 194
  • 1
  • 148
  • 17
  • 396
  • 1237
  • 588
  • 29
  • 49
  • 3
  • 1162
  • 1237
  • 6
  • 3
  • 1240

Found 1243 All Conditions trials

A listing of All Conditions medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

18 years - 75 years
All genders
Phase 3
Interventional
This research study is being done to investigate how safe and effective the investigational drug brepocitinib is for treating dermatomyositis. If you agree to join the study, you will be asked to complete the following research procedures: • signing this informed consent • having reviews of your medical/health history and …
99 years or below
All genders
Phase 2
Interventional
The main purpose of this study is to evaluate the efficacy and safety of the investigational drug iptacopan (LNP023) in people with primary ITP or primary CAD. You will be in the study about 6 months with the opportunity to extend the total duration to about 31 months if you …
18 years - 99 years
All genders
Phase 1
Interventional
This study involves research of an investigational therapy called SynKIR-110. SynKIR-110 is CAR T cell therapy. CAR T cell therapy is a type of treatment in which a patient’s T cells (white blood cells that are a part of the immune system) are changed in a laboratory so they can …
99 years or below
All genders
This is a prospective pilot study in which all eligible subjects will be randomized to treatment in the first phase and those with persistent or recurrent heart failure after Phase 1 therapy, may subsequently qualify to be randomized into Phase 2.
99 years or below
All genders
A Single-blind, Phase 2, Multi-center, Randomized Study to Assess Safety, Tolerability, Efficacy and Pharmacokinetics of the Relaxin Agonist R2R01 Plus Terlipressin Versus Terlipressin Alone in Patients with Hepatorenal Syndrome-Acute Kidney Injury
99 years or below
All genders
Requesting a reliance agreement with an external IRB. Study to evaluate pharmacokinetics, safety/tolerability, and immunogenicicty of ocrelizumab admistered subcutaneously in patients with MS. Pre-treated patients will be randomized (1:1) to dose-escalated, subcutaneous or IV administration. Treatment naive patients receive dose-escalated, subcutaneous administration only. All participants may then enter a dose …
99 years or below
All genders
This is a prospective, observational study designed to evaluate the long-term safety and efficacy of RGX-314. Eligible participants are those who were previously enrolled in a clinical study in which they received a single subretinal administration of RGX-314 (IRB #827859). Participants will be followed for up to 5 years post-RGX-314 …
99 years or below
All genders
This study will evaluate the potential placental transfer of ocrelizumab in women with clinically isolated syndrome (CIS) or multiple sclerosis (MS) [in line with the locally approved indications] whose last dose of ocrelizumab was administered any time from 6 months before the last menstrual period (LMP) through to the first …
99 years or below
All genders
This is a retrospective study funded by Vericel Corporation with the goal of collecting clinical characteristics of patients receiving MACI implantation in the patella as part of their standard clinical care as well as patient reported outcome measures.
99 years or below
All genders
Phase 1
This dual-site, double-blinded, randomized, sham-controlled, crossover study is to assess the safety, feasibility, and preliminary efficacy of SEEG-guided multi-lead DBS in 10 participants suffering from severe symptoms of chronic, treatment-refractory OCD. Stage 1: Invasive SEEG Monitoring and Recovery Goal: To perform stimulation mapping studies and SEEG recordings, that aid in …
691 - 700 of 1243